An interaction between aspirin and valproate: The relevance of plasma protein displacement drug-drug interactions

American Journal of Psychiatry

Volumn 163, Issue 11, 2006, Pages 1891-1896

  Sandson, Neil B ^a,b   Marcucci, Catherine ^a   Bourke, Denis L ^a   Smith Lamacchia, Rosemary ^a  

^a BALTIMORE VA MEDICAL CENTER   (United States)

^b SHEPPARD PRATT HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GABAPENTIN; NEUROLEPTIC AGENT; NORTRIPTYLINE; VALPROATE SEMISODIUM; VALPROIC ACID;

AGED; ANAMNESIS; BIPOLAR I DISORDER; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG TOLERANCE; GRANDIOSE DELUSION; HEALTH STATUS; HUMAN; HYPERLIPIDEMIA; MALE; MINI MENTAL STATE EXAMINATION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PARANOIA; PRIORITY JOURNAL;

EID: 33751320419     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2006.163.11.1891     Document Type: Conference Paper

References (22)

1. Grymonpre RE, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR: Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 1988; 36:1092-1098
2. Glassman PA, Simon B, Belperio P, Lanto A: Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002; 40:1161-1171
3. Einarson TR, Metge CJ, Iskedjian M, Mukherjee J: An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther 2002; 24:2126-2136
4. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA: Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289:1652-1658
5. Farrell K, Orr JM, Abbott FS, Ferguson S, Sheppard I, Godolphin W, Bruni J: The effect of acetylsalicylic acid on serum free valproate concentrations and valproate clearance in children. J Pediatr 1982; 101:142-144
6. Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W: Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects. Clin Pharmacol Ther 1982; 31:642-649
7. Goulden KJ, Dooley JM, Camfield PR, Fraser AD: Clinical valproate toxicity induced by acetylsalicylic acid. Neurology 1987; 37:1392-1394
8. Pisani F: Influence of co-medication on the metabolism of valproate. Pharm Weekbl Sci 1992; 14(3A):108-113
9. Abbott FS, Kassam J, Orr JM, Farrell K: The effect of aspirin on valproic acid metabolism. Clin Pharmacol Ther 1986; 40:94-100
10. Regardh CG, Gabrielsson M, Hoffman KJ, Lofberg I, Skanberg I: Pharmacokinetics and metabolism of omeprazole in animals and man - an overview. Scand J Gastroenterol Suppl 1985; 108:79-94
11. Wen X, Wang JS, Kivisto KT, Neuvonen PJ, Backman JT: In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001; 52:547-553
12. Cadle RM, Zenon GJ 3rd, Rodriguez-Barradas MC, Hamill RJ: Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 1994; 28:191-195
13. Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N: The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998; 39:1317-1323
14. Perucca E, Hebdige S, Frigo GM, Gatti G, Lecchini S, Crema A: Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 1980; 28:779-789
15. Cloyd J: Pharmacokinetic pitfalls of present antiepileptic medications. Epilepsia 1991; 32(suppl 5):S53-S65
16. Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE: Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 1997; 283:698-703
17. Bottiger Y, Svensson JO, Stahle L: Lamotrigine drug interactions in a TDM material. Ther Drug Monit 1999; 21:171-174
18. Chetty M, Miller R, Seymour MA: Phenytoin auto-induction. Ther Drug Monit 1998; 20:60-62
19. Ritter JK, Kessler FK, Thompson MT, Grove AD, Auyeung DJ, Fisher RA: Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Hepatology 1999; 30:476-484
20. Miners JO: Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin Pharmacokinet 1989; 17:327-344
21. Paxton JW: Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects. Clin Pharmacol Ther 1980; 27:170-178
22. Levy RH, Schmidt D: Utility of free level monitoring of antiepileptic drugs. Epilepsia 1985; 26:199-205